Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy.
Kifjak D, Hochmair M, Sobotka D, Haug AR, Ambros R, Prayer F, Heidinger BH, Roehrich S, Milos RI, Wadsak W, Fuereder T, Krenbek D, Fazekas A, Meilinger M, Mayerhoefer ME, Langs G, Herold C, Prosch H, Beer L.
Kifjak D, et al.
Eur J Radiol. 2024 Jan;170:111198. doi: 10.1016/j.ejrad.2023.111198. Epub 2023 Nov 21.
Eur J Radiol. 2024.
PMID: 37992608
Free article.